logo_Logologo_Logologo_Logologo_Logo
  • About Us
    • Corporate Overview
    • Executive Leadership
      • Management team
      • Scientific Advisory Board
      • Board of Directors
  • Our Science
    • Pipeline
      • Overview
      • AG-73305
      • AG-80308
      • AG-86893
    • Disease
      • Overview
      • DME
      • nAMD
      • Other Diseases
      • Pterygium
      • Dry Eye
    • Clinical Trial
  • Investor Relations
    • Investors
    • Press Release & Publications
  • Contact Us

News

  • 2022-06-20

    Allgenesis Announces First Patient Dosed in the U.S. for the Phase 1b trial Evaluating AG-80308 for the Treatment of Dry Eye Disease


    Read more
  • 2022-06-13

    Allgenesis Announces First Patient Enrollment in a FIH Phase 2a Trial of AG-73305 for the Treatment of Diabetic Macular Edema


    Read more
  • 2022-03-31

    Allgenesis Announces FDA Clearance of the IND for AG-73305 for the Treatment of Diabetic Macular Edema


    Read more
  • 2022-02-28

    Allgenesis Receives Notice of Grant of Patent for Fusion Protein of VEGF Trap and Disintegrin in China


    Read more
  • 2021-11-25

    Allgenesis Biotherapeutics Inc. – U.S. Patent Granted for Fusion Protein of VEGF Trap and Disintegrin


    Read more
logo_Logo

9F.-3, No.760, Sec. 4, Bade Rd.,
Songshan Dist., Taipei City 105,
Taiwan (R.O.C.)

Tel: +886-2-8787-1232
Fax: +886-2-8787-1239
Mail: info@allgenesis.com
Copyright © 2019 Allgenesis Biotherapeutics Inc. All rights reserved.